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a b s t r a c t
Polyomaviruses (PyVs) are associated with tumors including Merkel cell carcinoma (MCC). Several PyVs
encode microRNAs (miRNAs) but to date no abundant PyV miRNAs have been reported in tumors. To
better understand the function of the Merkel cell PyV (MCPyV) miRNA, we examined phylogenetically-
related viruses for miRNA expression. We show that two primate PyVs and the more distantly-related
raccoon PyV (RacPyV) encode miRNAs that share genomic position and partial sequence identity with
MCPyV miRNAs. Unlike MCPyV miRNA in MCC, RacPyV miRNA is highly abundant in raccoon tumors.
RacPyV miRNA negatively regulates reporters of early viral (T antigen) transcripts, yet robust viral miRNA
expression is tolerated in tumors. We also identify raccoon miRNAs expressed in RacPyV-associated
neuroglial brain tumors, including several likely oncogenic miRNAs (oncomiRs). This work describes the
ﬁrst PyV miRNA abundantly expressed in tumors and is consistent with a possible role for both host and
viral miRNAs in RacPyV-associated tumors.
& 2014 Elsevier Inc. All rights reserved.
Introduction
PyVs are small DNA viruses with 5 kilobase genomes that likely
infect most vertebrate species (Cole, 1996). There are at least 13
different human PyVs known and numerous PyVs have been identi-
ﬁed that infect other animals (DeCaprio and Garcea, 2013; Dela Cruz
et al., 2013; Leendertz et al., 2011; Ehlers and Moens, 2014). In a
majority of cases, infection with these viruses is asymptomatic.
However, in rare instances, typically involving immune suppression,
infection with some PyVs can result in serious disease (Dalianis and
Hirsch, 2013;White et al., 2013). Under laboratory conditions, infection
with PyVs can lead to a high incidence of tumors (Zhang et al., 2014).
In addition, two PyVs, McPyV and RacPyV, have been strongly
associated with tumors arising in natural settings. In humans, MCPyV
is associated with at least 80% of Merkel cell carcinomas (MCCs)
through a mechanism that typically involves integration of the viral
genome into tumor cells (Dela Cruz et al., 2013; Feng et al., 2008;
Brostoff et al., 2014; Shuda et al., 2008). Integration of the MCPyV
genome leads to expression of Tumor antigen (TAg) proteins derived
from the early viral genomic region in the absence of late gene
expression, consistent with the known transforming activities of the
laboratory model of PyV TAgs (An et al., 2012; Cheng et al., 2009; Fluck
and Schaffhausen, 2009). The fact that RacPyV-associated tumors
harbor predominantly episomal viral genomes (Dela Cruz et al.,
2013; Brostoff et al., 2014) suggests that the modes of RacPyV and
MCPyV-associated tumorigenesis are distinct.
We have previously shown that diverse PyVs encode miRNAs
(Seo et al., 2008; Seo et al., 2009; Chen et al., 2013; Sullivan et al.,
2005, 2009; Cantalupo et al., 2005). miRNAs are small regulatory
RNAs that are typically processed through a conserved set of
machinery, including the Drosha and Dicer nucleases (Bartel, 2009).
Once generated, miRNAs enter the RNA induced silencing complex
(RISC) where they bind to speciﬁc mRNAs and direct translation
inhibition and/or transcript turnover. Although PyV miRNAs can
vary in sequence and genomic position, all share the ability to
negatively regulate early viral gene expression (Cox and Sullivan,
2014; Kincaid and Sullivan, 2012; Lagatie et al., 2013). The con-
served nature of this activity implies importance, yet the functio-
nal role of the PyV miRNAs during natural infection and in
PyV-associated disease remains obscure.
To better understand the function of the MCPyV miRNAs, we
sought to apply a comparative evolutionary approach. Here we
uncover that primate PyVs closely related to MCPyV, and the more
distantly related RacPyV, each encode miRNAs of comparable
genomic location. Each of these miRNAs possesses the ability to
negatively regulate complementary regions of the early viral tran-
scripts. These results are consistent with miRNA-mediated regulation
of early gene expression being an important activity shared between
all known PyV miRNAs. We demonstrate that the RacPyV miRNA is
among the most abundant miRNAs detectable in RacPyV-associated
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tumors. This is in sharp contrast to the MCPyV-associated tumors
where our meta-analysis of published reports shows that the viral
miRNA is of extremely low abundance and unlikely to be bioactive.
Therefore, despite the likely ability of RacPyVmiRNAs to downregulate
early gene expression levels, RacPyV tumors (known to express early
T Antigen transcripts) readily tolerate high levels of the viral miRNA.
We also identify for the ﬁrst time numerous raccoonmiRNAs, including
several that are known oncogenic miRNAs (oncomiRs). Combined with
previous work (Dela Cruz et al., 2013; Brostoff et al., 2014), these
observations further support a different mode of tumorigenesis for the
MCPyV and RacPyV-associated tumors, and are consistent with a
possible role of viral miRNAs in RacPyV-associated tumors.
Materials and methods
Cell culture, tissue samples and RNA isolation
Human embryonic kidney 293 T cells (293 T) were obtained
from the American Type Culture Collection (Manassa, VA), wild
type 293 T and Dicer-deﬁcient 293 T cells were kind gifts from
Bryan Cullen (Duke University). All cell lines were maintained in
Dulbecco's modiﬁed Eagle's medium supplemented with 10% fetal
bovine serum (Life Technologies, Carlsbad, CA), 100IU/mL penicil-
lin, and 100 μg/mL streptomycin (Corning Cellgro, Manassas, VA).
Total RNA was harvested using an in-house PIG-B solution as
previously described (Seo et al., 2008; Chen et al., 2011; Lin et al.,
2010; Weber et al., 1998). Animals were submitted for routine
necropsy through the Veterinary Medical Teaching Hospital at UC
Davis. Cells obtained from Rac14 tumor tissue was cultured as
previously described (Brostoff et al., 2014). Brieﬂy, cells were
maintained in Neurobasal-A medium supplemented with N2 and
B27 supplements (Life Technologies) and 25 ng/mL of rhEGF and
bFGF (R&D Systems Inc, Minneapolis, MN). Raccoon brain tissue
samples were homogenized by placing the sample into Lysing
Matrix A tubes (MP Biomedicals, Solon, OH) along with one milliliter
of TRIzol RNA isolation reagents (Life Technologies) and subjected to
shaking in a Mini-Beadbeater-24 (Bartlesville, OK) at the fastest setting
for one minute followed by cooling on ice for one minute. The process
of homogenization and cooling was repeated three times. The lysate
was then centrifuged at 1000 G for one minute to pellet. The super-
natant was then transferred into four milliliters of TRIzol and subjected
to RNA isolation according to the manufacturer's protocol.
Computational prediction and selection of viral pre-miRNA
candidates
The complete genome sequences for Pan troglodytes verus poly-
omavirus 2a isolate 6512 (PtvPyV2a, accession number: HQ385748.1),
Gorilla gorilla gorilla polyomavirus 1 isolate 5766 (GggPyV1, accession
number: HQ385752.1) and Raccoon polyomavirus strain R45 (RacPyV,
accession number: JQ178241.1) were subjected to miRNA prediction
using VMir (Sullivan et al., 2005; Grundhoff et al., 2006; Sullivan and
Grundhoff, 2007). A minimum cutoff score of 150 was applied to the
pre-miRNA prediction for PtvPyV2a, GggPyV1 and RacPyV. Candidate
pre-miRNAs were selected for veriﬁcation if they met the following
two criteria: (1) found in the late orientation and (2) the predicted
genomic location of the pre-miRNA was either positioned similar to
SV40-like (Sullivan et al., 2005) or muPyV-like (Sullivan et al., 2009)
pre-miRNAs. The pre-miRNA candidate for each PyV was predicted
using the mfold RNA folding prediction web server (Zuker, 2003).
Construction of PyV phylogenetic tree
The phylogenetic tree was constructed based on the complete
genome sequences from the following PyVs: PtvPyV2a, GggPyV1,
RacPyV, SV40 (Accession number: J02400.1), JCV (Accession num-
ber: NC_001699.1), BKV (Accession number: NC_001538.1), Murine
Polyomavirus (Accession number: NC_001515.1), SA12 (Accession
number: AY614708.1), Merkel Cell Carcinoma virus, 350 (Accession
number: EU375803.1). The maximum likelihood phylogenetic tree
was generated as previously described (Chen et al., 2014). Brieﬂy,
the phylogenetic tree was constructed using the PhyML version
3.0 aLRT program from the web-based Phylogeny.fr software, under
the HKY85 substitution model. The SH-like approximate likelihood-
ratio test (aLRT) was applied to test for branch support (Dereeper
et al., 2008, 2010; Edgar, 2004; Guindon and Gascuel, 2003;
Anisimova and Gascuel, 2006; Chevenet et al., 2006). The resulting
phylogenetic tree was viewed using the FigTree software version 1.4.2
(tree.bio.ed.ac.uk/software/ﬁgtree/).
MiRNA expression vector construction, transfection, and northern blot
analysis
All DNA vector constructs were sequence veriﬁed through
sequence analysis at the Institute of Cellular and Molecular Biology
Sequencing Facility at the University of Texas at Austin. The
primers used in the construction of the pre-miRNA candidates
expression vectors have been listed in Table S1. Brieﬂy, the primers
are annealed and ﬁlled-in using Phusion High-Fidelity DNA poly-
merase (New England BioLabs, Ipswich, MA) according to the
manufacturer's protocol. The PCR products were then cloned into
the pcDNA3.1neo expression vector using the restriction sites
listed in Table S1. 293 T cells were plated in 6-well plates and
transfected with expression vector using the Lipofectamine 2000
transfection reagent (Life Technologies) according to the manu-
facturer's instruction. As a negative control, cells were transfected
with empty pcDNA3.1neo vector. Total RNA was harvested at 48 h
post transfection. The total RNAwas subjected Northern blot analysis
as described previously (Sullivan et al., 2005). Brieﬂy, 10 micrograms
of total RNA was separated on a Tris-borate-EDTA-urea-15% denatur-
ing polyacrylamide gel. The RNA was transferred onto a Hybond Nþ
membrane (GE Healthcare, Pittsburgh, PA). The probe sequences
used are listed in Table S2.
Drosha dependence assay
293 T cells were seeded in 6-well plates. Cells were transfected
with either the Silencer Select negative control siRNA (scrambled)
or a pool of 10 siRNAs against Drosha using the RNAiMAX transfection
reagent (Life Technologies) according to the manufacturer's instruc-
tions. At 12 h post siRNA transfection, the miRNA expression vectors
were co-transfected with Drosha siRNA or negative control siRNA
using the Lipofectamine 2000 transfection reagent (Life Technologies)
according to the manufacturer's instructions. Transfection of the SV40
miRNA expression vector was included as a positive control. Five
hundred ng of pIDT-MHV68 miR-M1-7, a plasmid that expresses the
Murid herpesvirus 68 (MHV68) M1-7 miRNA, was included in every
transfection to serve as an internal control. Total RNAwas harvested at
48 h post transfection and subjected to Northern blot analysis as
described above. For these assays, probes that recognized the corre-
sponding 5p derivative miRNA of each virus were utilized. For the
internal control MHV68 M1-7 miRNAs, the 3p derivative miRNA was
probed for. The probe sequences used are listed in Table S2.
Dicer dependence assay
Wild type 293 T cells or the Dicer-deﬁcient 293 T cells (Bogerd
et al., 2014b, 2014a) were seeded in 6-well plates and were transfected
at approximately 50% conﬂuency with the polyomaviral miRNA
expression vectors, using the TurboFect transfection reagent (Thermo
Scientiﬁc). Total RNAwas harvested at 48 h post transfection using the
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PIG-B solution (Weber et al., 1998) followed by Northern blot analysis
as described above. The SV40 miRNA expression vector and an empty
pcDNA3.1neo vector were used as the positive and negative controls,
respectively. The northern blot probes used are listed in Table S2.
Luciferase assays
The miRNA reporter plasmids were constructed by cloning the
genomic region corresponding to the pre-miRNA of each PyV in the
early (T antigen) orientation into the 30 UTR of dsRLuc (primers listed
in Table S1). To construct the RacPyV late region reporter plasmids, the
RacPyV genomic region that encodes the late mRNA was divided into
four overlapping fragments, each 500 bp in length, as listed in Table
S1. The four fragments were synthesized as gBlock gene fragments
(Integrated DNA Technologies). PCR products were generated using
Phusion High-Fidelity DNA polymerase (New England BioLabs) and
cloned into the pcDNA3.1dsRluc vector, which expresses a destabilized
version of the Renilla luciferase (using the restriction sites listed in
Table S1). 293 T cells were plated in 24-wells plates and transfected
using the TurboFect transfection reagent. The SV40 miRNA expression
vector (Chen et al., 2013) and the empty Renilla luciferase reporter
construct were included as negative controls. The pcDNA3.1luc2CP
vector, which expresses a destabilized version of the ﬁreﬂy luciferase,
was included in the transfection reactions to normalize for transfection
efﬁciency. Transfected cells were collected at 24 h post transfection
and analyzed with the Dual-luciferase reporter assay system (Pro-
mega, Fitchburg, WI) according to the manufacturer's instruction. The
luciferase readings were collected using a Luminoskan Ascent micro-
plate luminometer (Thermo Scientiﬁc). The readings from the Renilla
luciferase were normalized to the readings from the ﬁreﬂy luciferase,
with the ratios plotted as a bar graph relative to the empty Renilla
luciferase vector control.
Small RNA library and computational analysis of sequencing reads
293 T cells were seeded in 10 cm tissue culture dishes and
transfected with the PtvPyV2a, GggPyV1 or the RacPyV miRNA
expression vector using the Lipofectamine 2000 transfection reagent
(Life Technologies). Total RNA was harvested at 48 h post transfec-
tion. Two raccoon brain tumor tissue samples (Rac 12 and Rac 14)
were homogenized and total RNA was harvested as described above.
Small RNAs from the transfected 293 T cells and the brain tumor
tissue samples were gel fractionated as previously described (Chen
et al., 2013; Lin et al., 2010). The small RNA cDNA library was
generated using the NEBNext Multiplex Small RNA library prep set
for Illumina kit (New England BioLabs) according to the manufac-
turer's instructions. The resulting cDNA library was then subjected to
paired-end sequencing on the Illumina HiSeq (Illumina, San Diego,
CA) as previously described (Chen et al., 2013). Brieﬂy, the PtvPyV2a,
GggPyV1 and RacPyV small RNA reads were mapped onto the
respective virus genomes. The raccoon miRNAs from the tumor
tissue samples were mapped to the mouse mature miRNA sequences
build on miRBase (Grifﬁths, 2004; Grifﬁths-Jones, 2006; Grifﬁths-
Jones et al., 2008; Kozomara and Grifﬁths-Jones, 2011; Kozomara and
Grifﬁths-Jones, 2014), without allowing for any mismatches. To
annotate each raccoon miRNA as an oncogene or a tumor suppressor,
each miRNA was referenced to two independent databases, the
OncomiRDB (Wang et al., 2014) and miRCancer (Xie et al., 2013).
Results
PyVs closely related to MCPyV also encode miRNAs.
We have previously demonstrated that multiple members of
the PyV family encode miRNAs (Seo et al., 2008, 2009; Chen et al.,
2013; Sullivan et al., 2005, 2009; Cantalupo et al., 2005). To better
understand the functions of the MCPyV miRNAs, we applied a
comparative evolutionary approach to search for miRNAs in
viruses related to MCPyV. To this end, we turned our attention
to three recently discovered, non-human PyVs that are related to
MCPyV (Dela Cruz et al., 2013; Leendertz et al., 2011). Pan troglodytes
verus polyomavirus 2a (PtvPyV2a) and Gorilla gorilla gorilla polyoma-
virus 1 (GggPyV1) are two of the closest known relatives of MCPyV,
whereas the raccoon polyomavirus (RacPyV) is more distantly related
to MCPyV (Fig. 1A). Using the vMir pre-miRNA prediction algorithm
(Sullivan et al., 2005; Grundhoff et al., 2006; Sullivan and Grundhoff,
2007), we identiﬁed pre-miRNA candidates from all three PyVs. In
all three viruses, pre-miRNA candidates were found at similar genomic
locations to the known pre-miRNA encoded by MCPyV
(data not shown, (Seo et al., 2009; Sullivan et al., 2009)).
To test the validity of these candidate pre-miRNAs, an approximately
140 base pair (bp) portion of each PyV sequence (encompassing the
pre-miRNA candidate and ﬂanking genomic regions) was synthesized
and cloned into individual expression vectors. We then transfected the
expression vectors into 293 T cells, harvested total RNA, and conducted
Northern blot analysis. The results showed that all three candidates give
rise to abundant bands consistent with the size and processing pattern
of known miRNAs (Fig. 1B to G). Similar to the MCPyV miRNA, the 5p
derivative miRNAs (Fig. 1B, D and F) were detected at a greater
abundance than their 3p derivative counterparts (Fig. 1C, E and G) for
PtvPyV2a, GggPyV1 and RacPyV. We note that this Northern blot
analysis showed extensive cross-reactivity between the probes for the
PtvPyV2a and GggPyV1 candidates (Fig. 1B and D), likely due to the
high sequence similarity (86% identity) between the pre-miRNA
genomic regions of these two viruses. These data are consistent with
these viruses encoding miRNAs in the same genomic region as MCPyV.
Next, using Illumina high throughput sequencing, we charac-
terized the small RNAs derived from the PtvPyV2a, GggPyV1, RacPyV,
and MCPyV candidate pre-miRNA expression vectors. 293 T cells were
transfected with individual expression vectors and total RNA was size
fractionated to enrich for small RNAs. We generated cDNA libraries
from these small RNAs and conducted deep sequencing using the
Illumina platform (Fig. 2). The predominant derivative RNAs displayed
all the features expected of true miRNAs including: appropriate size
(22 nucleotides), ability to ligate to library linkers (demonstrating
correct end structure), and mapped position within the putative
hairpin pre-miRNA structure. We conclude that PtvPyV2a, GggPyV1
and RacPyV viruses encode bona ﬁde miRNAs.
This deep sequencing analysis revealed that, consistent with
the Northern blot results, the 5p derivative miRNAs for all three
pre-miRNA expression vectors (PtvPyV2a, GggPyV1 and RacPyV)
are dominant (Fig. 2A–C). We also detected 5' end heterogeneity
for most of these 5p miRNAs, which likely explains earlier appar-
ently contradictory reports (Seo et al., 2009; Lee et al., 2011)
identifying MCPyV 5p miRNA start sites that differ by 2 nucleotides.
These sequences reveal extensive identity between the PtvPyV2a,
GggPyV1, and MCPyV miRNAs including shared seed sequences
(Fig. 2D). In contrast, the RacPyV miRNA shared only limited
sequence identity with the MCPyV miRNA. We conclude that the
miRNAs from PtvPyV2a, GggPyV1 and MCPyV, and possibly RacPyV,
are orthologous.
The PtvPyV2a, GggPyV1 and RacPyV miRNAs derive
from canonical mechanisms
Although most host miRNAs are produced from canonical
Drosha/Dicer-dependent processing, there are several viral miRNAs
that arise via non-conventional mechanisms (Cazalla et al., 2011;
Kincaid et al., 2014; Whisnant et al., 2014; Diebel et al., 2014, 2010;
Feldman et al., 2014; Pfeffer et al., 2005; Bogerd et al., 2010). To
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determine if canonical miRNA biogenesis machinery contributes to
the abundance of the PtvPyV2a, GggPyV1 and RacPyV miRNAs, we
transfected 293 T cells with an siRNA to knockdown Drosha and then
individually transfected cells with expression vectors for either the
PtvPyV2a, GggPyV1 or RacPyV miRNAs. We then performed northern
blot analysis on total RNA harvested from these cells. This showed
that knockdown of Drosha led to a substantial decrease in the pre-
miRNA signals for all the miRNAs we tested (Fig. 3A). As expected,
these results mirrored the results for cells transfected with our
positive control SV40 miRNA expression vector, but not the negative
control MHV68 miR-M1-7 whose biogenesis is independent of
Drosha processing (Bogerd et al., 2010; Kincaid et al., 2012). Thus,
the PtvPyV2a, GggPyV1 and RacPyV genomes encode miRNAs whose
biogenesis is dependent on Drosha processing.
Almost all known miRNAs depend on the Dicer nuclease for
maturation of the pre-miRNA to ﬁnal effector miRNA. To determine if
the biogenesis of PtvPyV2a, GggPtV1 and RacPyV miRNAs is dependent
on Dicer, the PtvPyV2a, GggPyV1 or RacPyV miRNA expression vectors
were transfected into either wild type 293 T or Dicer-deﬁcient 293 T
cells (Bogerd et al., 2014b, 2014a), followed by Northern blot analysis of
the total RNA. For all three miRNAs tested, there was less detectable
mature miRNA signal and a corresponding build-up of the pre-miRNA
signals in the Dicer-deﬁcient cell line (Fig. 3B). The increase in the ratio
of pre-miRNA-to-miRNA bands for PtvPyV2a, GggPyV1 and RacPyVwas
also observed for the control SV40 miRNA and MHV68 M1-7 miRNAs,
whichwere previously demonstrated to be Dicer-dependent (Kincaid et
al., 2012). These results demonstrate that the PtvPyV2a, GggPyV1 and
RacPyV genomes encode miRNAs whose biogenesis is dependent on
Dicer processing.
The PtvPyV2a, GggPyV1 and RacPyV miRNAs negatively
regulate early viral transcripts
Similar to all other known polyomaviral miRNAs, the PtvPyV2a,
GggPyV1, and RacPyV miRNAs are located antisense to the viral early
Fig. 1. PtvPyV2a, GggPyV1 and RacPyV encode miRNAs. (A) Phylogenetic analysis of all PyVs that are known to encode miRNAs. A Phylogenetic tree was constructed based
on the complete genome sequence of all known miRNA-expressing PyVs. The phylogeny was determined using a maximum likelihood analysis and represented as a
cladogram. The three PyVs studied in this report are boxed and shown in bold. (B – G) Northern blot conﬁrms miRNA expression. The pre-miRNA candidate from each PyV
was cloned into a heterologous expression vector and transfected into 293 T cells. Total RNA was subjected to Northern blot analysis. Probes designed to recognize the
(B) PtvPyV2a 5p, (C) PtvPyV2a 3p, (D) GggPyV1 5p, (F) GggPyV1 3p, (G) RacPyV 5p and (H) RacPyV 3p were used. As controls, cells were transfected with either the empty
pcDNA3.1neo vector (lane “N”) or an SV40 miRNA expression vector (lane “S”). As positive controls, the blots were probed for either the SV40 3p miRNA or the cellular
miRNA, let-7a. The bands corresponding to the pre-miRNAs (white arrowhead), the 5p derivative miRNAs (black arrowhead) and the 3p derivative miRNAs (gray arrowhead)
are indicated. Ethidium bromide-stained low-molecular-weight RNA served as a loading control. The identity of each lane is indicated at the top of each blot as follows:
2¼PtvPyV2a, G¼GggPyV1 and R¼RacPyV.
C.J. Chen et al. / Virology 476 (2015) 43–5346
transcripts. Therefore, we hypothesized that, similar to other poly-
omaviral miRNAs (Seo et al., 2008, 2009; Chen et al., 2013; Sullivan et
al., 2005, 2009), these miRNAs can regulate early transcripts. To test
this, we generated luciferase reporters containing the corresponding
genomic region from the early transcripts. As expected, co-
transfection of the PtvPyV2a, the GggPyV1 or the RacPyV miRNA
expression vectors with the negative control reporter plasmid had no
effect on luciferase activity (Fig. 3C). However, co-transfection of any
of the three individual miRNA expression vectors, with their appro-
priate corresponding reporter, demonstrated a signiﬁcant reduction
in luciferase activity (Fig. 2C). Interestingly, we observed extensive
cross reactivity of the PtvPyV2a miRNA on the GggPyV1 reporter,
likely due to the extensive sequence similarity between these viruses.
Combined, these results demonstrate that the PtvPyV2a, GggPyV1
and RacPyV miRNAs are fully active in RISC, and suggest that these
miRNAs can regulate early transcript expression.
The RacPyV miRNA is highly expressed in tumors
RacPyV was ﬁrst discovered in neuroglial frontal/olfactory lobe
tumors in free-ranging raccoons in the Western United States, and
100% of these tumors (19/19) contain RacPyV DNA (Dela Cruz et al.,
2013). To determine if the RacPyV miRNAs are expressed in
tumors, we conducted northern blot analysis on RNA harvested
from four different RacPyV-associated tumors (Rac 10, 12, 14 and
16). The RacPyV 5p derivative miRNA was readily detectable in all
four tumor tissue samples, but not in the RacPyV-negative non-
tumor raccoon tissue (Fig. 4A). To rule out that the miRNA signal
we detected was due to non-speciﬁc RNA degradation, we stripped
and re-probed our blots with control probes designed to recognize
the terminal loop and ﬂanking regions of the RacPyV pre-miRNA
(which should not be processed into stable 22 nt RNAs). These
probes failed to detect speciﬁc bands thereby demonstrating the
speciﬁcity of the miRNA probes (data not shown). These results
demonstrate that the RacPyV miRNA is readily detectable in tumors.
The above northern blot results suggested that the RacPyV
miRNA is abundant in tumors. To better characterize the miRNAs
in RacPyV tumors we deep sequenced small RNAs from two different
tumors. This analysis showed that both in sequence and 5p dom-
inance of the derivative miRNAs, the RacPyV miRNAs in tumors are
identical to those we characterized in our transfection studies
(Fig. 2C) (Fig. 4B and C). This analysis also identiﬁed numerous host
(raccoon) miRNAs that share sequence identity with known miRNAs
from other mammals, including some that have been reported as
having oncogenic properties (oncomiRs) (Table 1). Importantly, in
both tumor samples analyzed, the RacPyV miRNA was among the
most abundant miRNAs detectable in our libraries (6th and 12th
most abundant, Table 1, Figs. S1 and S2). These data uncover for the
ﬁrst time abundant viral miRNAs in a PyV-associated tumor, and
suggest the possibility that viral and host miRNAs are active in the
progression or stability of the tumor.
It has been previously demonstrated that in cultured primary
tumor cells, RacPyV genome is continually maintained throughout
multiple passages (Brostoff et al., 2014). To determine if the
expression of the RacPyV miRNA is also maintained, total RNA
was harvested from cultured cells from the Rac 14 tumor at
passage 5 and passage 20. Northern blot analysis indicated that
the RacPyV 5p derivative miRNA is detectable at comparable
intensities in both the early and the late passage cells (Fig. 4D).
This suggests that the RacPyV miRNA is stably maintained throughout
passage. We also tested whether the RacPyV miRNA is detectable in
RacPyV-associated mouse xenograft tumors (Brostoff et al., 2014).
These tumors arise from implantation of the RacPyV tumor cell lines
into NOD scid gamma mice (http://jaxmice.jax.org/nod-scid-gamma/).
Similar to the naturally arising tumors in the wild, northern blot
analysis conﬁrmed the RacPyV 5pmiRNAwas readily detectable in the
xenograft tumors. Combined, these data demonstrate that expression
of the RacPyV miRNA is not prohibitive to tumor cell growth and are
consistent with a possible pro-tumorigenic activity of this miRNA.
The MCPyV miRNA is unlikely to be biologically relevant
in tumors
Given that RacPyV and MCPyV are phylogentically related and
both are associated with tumors, we wanted to determine if
Fig. 2. The PtvPyV2a, GggPyV1 and RacPyV miRNAs are partially conserved. (A – C)
Coverage plot of the small RNA deep sequencing reads from (A) PtvPyV2a,
(B) GggPyV1 and (C) RacPyV miRNA expression-vector-transfected 293 T cells.
The number of reads (y axis) was mapped onto the corresponding PyV genome
(x axis). The black bars indicate the start position of each miRNA and the coverage
is represented by the gray ﬁlled area. All three PyVs produce dominant 5p
derivative miRNAs (indicated in the red boxes) and less abundant 3p derivative
miRNAs (indicated in the blue boxes). Each miRNA sequence is indicated above its
corresponding peak, with the seed sequences (nucleotide positions 2 to 8) under-
lined. The 5p (red) and 3p (blue) derivative miRNAs are indicated in each hairpin
structure, with their seed sequence underlined. PtvPyV2a expresses two different
species of the 5p derivative miRNAs. The seed sequences of the major and minor
species are underlined and highlighted in green, respectively, in the hairpin
structure. (D) The PtvPyV2a, GggPyV1 and RacPyV miRNAs share partial sequence
identity with the MCPyV miRNAs. Sequence alignment of the 5p and 3p derivative
miRNAs from PtvPyV2a, GggPyV1a and RacPyV and MCPyV miRNA sequences
(Seo et al., 2009; Lee et al., 2011). The 5' and 3' coordinates of each derivative
miRNA are indicated and the seed sequence for each miRNA is underlined. The seed
sequences from the major and minor form of the PtvPyV2a 5p derivative miRNAs
are underlined and highlighted in green respectively. The seed sequence from the
MCPyV 5p derivative miRNA reported by Lee et al. and Seo et al. Seo et al., (2009;
Lee et al., 2011) are underlined and highlighted in green respectively.
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similar to RacPyV-associated tumors, the MCPyV miRNA was a
likely regulator of gene expression in tumors. Previously, Lee et al.
identiﬁed MCPyV miRNA expression in MCCs, and had suggested
that host targets of this miRNA may be involved in tumor biology
of MCCs (Lee et al., 2011). More recently, Renwick et al. collected a
larger deep sequencing dataset on small RNAs from multiple
independent MCC tumor samples (Renwick et al., 2013). To determine
the plausibility that the MCPyV miRNA is important in tumor biology,
we analyzed the existing published MCC tumor small RNA-seq
libraries (Lee et al., 2011; Renwick et al., 2013; Ning et al., 2014) to
Fig. 3. The PtvPyV2a, GggPyV1 and RacPyV miRNAs can negatively regulate early transcripts. (A) The biogenesis of PtvPyV2a, GggPyV1 and RacPyV miRNAs are Drosha
dependent. 293 T cells were transfected with an siRNA against Drosha or an irrelevant siRNA followed by co-transfection of the miRNA expression vectors with the siRNAs.
Northern blot analysis was performed on the total RNA at 48 h post transfection. The SV40 miRNA expression vector and the MHV68 miR-M1-7 expression vector were
transfected as positive and negative control, respectively. The bands corresponding to the pre-miRNAs (white arrowheads) are indicated. Ethidium bromide-stained low-
molecular-weight RNA served as a loading control. Irrelevant siRNA transfections are indicated by the “-” lanes and the Drosha siRNA transfections are indicated by the “þ”
lanes. (B) The biogenesis of PtvPyV2a, GggPyV1 and RacPyV miRNAs are Dicer dependent. Wild type or Dicer-deﬁcient 293 T cells indicated with þ or -, respectively are
transfected with the corresponding miRNA expression vector. Northern blot analysis was performed on the total RNA at 48 h post transfection. The SV40 miRNA and MHV68
miR-M1-7 expression vectors were transfected as positive controls. The bands corresponding to the pre-miRNAs (white arrowheads) and the mature miRNAs (black
arrowheads) are indicated. As a loading control, ethidium bromide_stained low-molecular-weight RNA is shown. (C) The PtvPyV2a, GggPyV1 and RacPyV miRNAs can
autoregulate early mRNA expression. The antisense Renilla luciferase construct for each of the three PyV was co-transfected with the ﬁreﬂy luciferase and various miRNA
expression vectors into 293 T cells. Normalized R. Luc for the different reporter constructs is shown. As a negative control, the empty pcDNA3.1neo vector was utilized. To
show speciﬁcity of the reporter assay, an SV40 miRNA expression vector was co-transfected with a reporter construct containing the SV40 miRNA binding sites in the 3' UTR.
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determine the relative abundance of the MCPyV miRNAs. This meta-
analysis showed that the MCPyV miRNA is only detectable in less than
half of MCPyV-positive MCC tumors (Table 2). When present, the
McPyV miRNA is not detectable at high levels, as it ranks among the
least abundant miRNAs in the 6 MCC tumors and cell lines analyzed
(Table 3). Given that miRNAs that are expressed at low levels (less than
0.1% of total miRNA reads or less than 100 copies/ cell) are unlikely to
be of functional signiﬁcance (Cullen, 2011; Brown et al., 2007), we
conclude that MCPyV miRNAs are not relevant regulators of gene
expression in tumor cells, at least by the current understanding of
canonical miRNA function. Combined with previous publications
(Dela Cruz et al., 2013; Brostoff et al., 2014), these results further
emphasize the differences in MCPyV and RacPyV-associated tumors.
Discussion
The fraction of PyVs that encode miRNAs and their functional
relevance remain poorly understood (Imperiale 2014). In this
work, we have applied a comparative evolutionary approach to
MCPyV and related viruses to better understand PyV miRNA
function. We demonstrate that closely related gorilla and chim-
panzee PyVs, as well as the more distantly related RacPyV, encode
miRNAs in similar genomic locations (Fig. 1). As predicted by the
genomic location, each of these newly-discovered miRNAs are
active at directing repression of PyV-early-gene-reporter chimeric
transcripts (Figs. 1 and 3). This suggests a functional role for the
MCPyV and related miRNAs in the negative regulation of early
Fig. 4. The RacPyV miRNA is detected in RacPyV-associated tumors and cell lines. (A) The RacPyV miRNA are detectable in RacPyV-associated raccoon brain tumors. Total
RNA was harvested from four different RacPyV-associated raccoon brain tumor samples (labeled as 10, 12, 14 and 16) and one normal raccoon brain sample (labeled N) and
subjected to Northern blot analysis. A probe designed to recognize the RacPyV 5p derivative miRNA was used. (B and C) The RacPyV miRNAs expressed in tumor tissues are
identical to the transfection samples. The number of small RNA deep sequencing reads from two RacPyV-associated tumor tissues, Rac 12 and 14, were mapped onto the
RacPyV genome. The 5p and 3p derivative miRNAs are indicated on top of each peak and indicated by a red box and a blue box, respectively, with the seed sequences
(nucleotide position 2 to 8) underlined. (D) The RacPyV miRNA is preserved throughout passage in cultured tumor cells and detectable in the mouse xenograft system. Total
RNA from an early and late passage of tumor cultures derived from the Rac 14 tumor, and two different Rac 14 derived mouse xenograft tumors, were subjected to Northern
blot detection of the RacPyV 5p derivative miRNA. The tumor cell lines are indicated at the top of the blot as follows: tumor cultures passages 5 and 20 (lanes “P5” and “P20”),
mouse xenograft tumor (lanes “A2” and “A5”). Small RNAs isolated from the Rac14 tumor were included as a control (lane “T”). Also, 293 T cells were transfected with either
the empty pcDNA3.1neo vector (indicated as “-”) or the RacPyV miRNA expression vector (indicated as “þ”). As a control, the blot was stripped and re-probed for the cellular
miRNA, let-7a. The bands corresponding to the pre-miRNAs (white arrowhead) and 5p derivative miRNA (black arrowhead) are indicated. As a loading control, ethidium
bromide-stained low-molecular-weight RNA is shown.
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gene expression, consistent with all other known PyV miRNAs
(Seo et al., 2008, 2009; Chen et al., 2013; Sullivan et al., 2005,
2009; Cantalupo et al., 2005).
In addition to a role in regulating the early transcripts, the
sequence similarity between MCPyV and related viruses is also
consistent with other shared common targets. Our work demon-
strates that PtvPyV2a and GggPyV1 share high sequence identity
with the MCPyV miRNA (Fig. 2D). The 5p derivative miRNA
encoded by RacPyV also shares partial sequence identity (10 out
of 22 nucleotides on a shifted alignment, Fig. 2D) with the 5p
derivative miRNA of MCPyV. This might be unexpected since
RacPyV and MCPyV are presumably separated by over 94 million
Table 1
Small RNA deep sequencing mapping of RacPyV and raccoon miRNAs. Small RNA deep sequencing reads from the Rac 12 and Rac 14 tumor tissue samples were mapped onto
the RacPyV genome or the miRBase miRNA database. The top ﬁfty most abundant raccoon miRNAs were calculated for each sample and listed according to their abundance.
The RacPyV 5p derivative miRNA is indicated in bold, underlined and highlighted in yellow. Each raccoon miRNA was designated as an oncogene (“O”), a tumor suppressor
(“TS”) or both, according to the annotation from two different databases, OncomiRDB (Wang et al., 2014) and miRCancer (Xie et al., 2013). A miRNA is designated “NA” when
it failed to match any annotation in both of the databases. Raccoon miRNAs that were sequenced from both tumor specimens are shaded in gray.
miRNAs Rac 12 miRNAs Rac 14
Counts OncomiRDB miRCancer Counts OncomiRDB miRCancer
mmu-miR-423-5p 240,090 na O mmu-miR-23b 800,100 Both Both
mmu-miR-191-5p 230,969 Both Both mmu-let-7a 781,650 TS TS
mmu-miR-23b 221,848 Both Both mmu-miR-15b 684,100 Both Both
mmu-miR-320a 220,030 TS TS mmu-miR-184 564,300 Both Both
mmu-miR-99a 203,606 TS Both mmu-miR-191 385,800 Both Both
mmu-miR-184 176,451 Both Both RacPyV 220,456
mmu-let-7a 167,357 TS TS mmu-miR-101 177,600 Both TS
mmu-miR-335-5p 166,738 Both Both mmu-miR-99a 176,800 TS Both
mmu-miR-342-3p 158,181 TS TS mmu-mir-320a 176,500 TS TS
mmu-miR-204-3p 121,788 na Both mmu-miR-342 176,300 TS TS
mmu-miR-24-3p 94,515 Both Both mmu-mir-423-5p 165,600 na O
RacPyV 77,568 mmu-miR-185-5p 162,200 TS Both
mmu-miR-718 73,838 na na mmu-miR-1a 144,500 TS TS
mmu-miR-140-3p 73,835 TS Both mmu-miR-24-3p 144,400 Both Both
mmu-miR-3195 73,693 na na mmu-miR-204 110,800 na Both
mmu-miR-320b 73,440 na na mmu-miR-503-5p 107,700 TS Both
mmu-miR-4634 73,115 na na mmu-miR-335 103,600 Both Both
mmu-miR-188 69,885 na na mmu-miR-195-5p 103,300 TS Both
mmu-miR-6087 63,857 na na mmu-miR-140-3p 100,900 TS Both
mmu-miR-3613-3p 58,992 na na mmu-miR-9-3p 90,727 na Both
mmu-miR-330-3p 51,746 na TS mmu-miR-214-3p 90,454 Both Both
mmu-miR-503-5p 33,063 TS Both mmu-miR-92b-5p 90,000 na na
mmu-miR-669 33,054 na na mmu-miR-140-5p 86,818 na TS
mmu-miR-6724-5p 31,560 na na mmu-miR-320b 86,454 na na
mmu-miR-4306 30,960 na na mmu-miR-6087 83,181 na na
mmu-miR-4484 30,960 na na mmu-miR-4484 78,090 na na
mmu-miR-4306þT 30,600 na na mmu-miR-30d-5p 74,030 Both Both
mmu-miR-129-2-3p 28,800 na TS mmu-miR-188 72,820 na na
mmu-miR-30d-5p 22,320 Both Both mmu-miR-671-5p 72,490 na na
mmu-miR-195-5p 21,600 TS Both mmu-miR-208b-3p 71,060 na na
mmu-miR-214-3p 18,360 Both Both mmu-miR-129-1-3p 68,200 na TS
mmu-miR-3178 18,360 na na mmu-miR-874 68,181 TS TS
mmu-miR-4442 16,200 na na mmu-miR-501-3p 68,090 na O
mmu-miR-7847-3p 16,200 na na mmu-miR-378a-3p 67,980 na TS
mmu-miR-4459 15,120 na na mmu-miR-486-3p 66,440 na na
mmu-miR-92b-5p 12,960 na na mmu-miR-494-3p 64,790 TS Both
mmu-miR-185-5p 12,600 TS Both mmu-miR-125a 60,060 TS TS
mmu-miR-3960 11,160 na na mmu-miR-3960 55,770 na na
mmu-miR-486-3p 11,160 na na mmu-miR-93-5p 50,600 Both Both
mmu-miR-343 10,440 na na mmu-miR-142 50,500 na Both
mmu-miR-378a-3p 10,440 na TS mmu-miR-6836-3p 48,700 na na
mmu-miR-8485 8280 na na mmu-miR-6880-5p 48,200 na na
mmu-miR-494-3p 6840 TS Both mmu-miR-718 47,800 na na
mmu-miR-5880 5040 na na mmu-miR-4306 47,200 na na
mmu-miR-652-5p 5040 na na mmu-miR-4459 46,600 na na
mmu-miR-93-5p 3000 Both Both mmu-miR-3613-3p 32,600 na na
mmu-miR-874-3p 2400 TS TS mmu-miR-669 31,200 na na
mmu-miR-124-3p 1297 Both TS mmu-miR-4442 31,000 na na
mmu-miR-99b-5p 1200 TS TS mmu-miR-652-5p 30,600 na na
mmu-miR-940 980 na na mmu-miR-8485 30,400 na na
mmu-miR-27b 645 Both Both mmu-miR-1307-5p 28,906 na na
Table 2
Meta-analysis of MCC tumor small RNA library data. Small RNA deep sequencing
reads were obtained from three independent studies on MCC tumors (Lee et al., 2011;
Renwick et al., 2013; Ning et al., 2014). The number of reads of mcv-miR-M1-5p








Total MCC tumors studied 52 2 14 68
MCPyV(þ) tumors 38 0 7 45
mcv-miR-M1-5p(þ) tumors 19 0 1 20
% of total miRNAs in MCPyV(þ)
tumors
0.005 0 0.025 0.002
C.J. Chen et al. / Virology 476 (2015) 43–5350
years of evolution when their respective raccoon and human hosts
diverged from a common ancestor (Hedges et al., 2006). Although
the shared sequences do not encompass identical shared seed
regions (Fig. 2D), the striking common sequence elements do
imply the possibility that RacPyV and MCPyV diverged from a
common miRNA locus precursor. If true, then this would represent
one of the oldest examples known of viral miRNA divergence from
a common ancestor.
Viral miRNAs have been established or suggested as playing a
role in various herpesviral-associated tumors. These include
chicken sarcomas associated with Marek's disease virus (MDV)
and various human lymphocyte and solid tumors associated with
Epstein Barr virus (EBV) and Kaposi's sarcoma-associated herpes-
virus (KSHV) (Yao and Nair 2014; Gottwein et al., 2011, 2007;
Skalsky et al., 2012; Boss et al., 2011; Seto et al., 2010; Vereide
et al., 2014; Dahlke et al., 2012). Additionally, we have identiﬁed a
miRNA encoded by the bovine leukemia retrovirus (BLV) that
mimics a known host oncogenic miRNA (Kincaid et al., 2012),
and this miRNA was later identiﬁed in BLV-associated tumors
(Rosewick et al., 2013). We have also previously shown that a
PyV-Papillomavirus hybrid virus, BPCV1, encodes a miRNA that is
readily detectable in tumors (Chen et al., 2011). However, to date,
no PyV miRNAs have been implicated in tumorigenesis.
Our ﬁnding that the RacPyV miRNA is among the most abundant
miRNAs in RacPyV-associated tumors opens up the possibility of a role
for viral miRNAs in these tumors. Our transfection-based reporter
studies suggest that the RacPyV miRNA can downregulate early
T antigen transcripts (Fig. 3C), yet enigmatically, early transcripts are
robust in tumors (Brostoff et al., 2014). Thus, despite the likely activity
of the RacPyV miRNA in reducing levels of a transforming early viral
protein(s) in some contexts (Fig. 3C), these tumors readily tolerate
robust levels of this miRNA (Fig. 4A). Several non-mutually exclusive
explanations could account for this. First, the relevant RacPyV trans-
forming proteins might result from a transcript that escapes RacPyV
miRNA regulation. For example, miRNA regulation could be blocked by
alternative splicing that eliminates the miRNA docking site in the
derivative mRNA or through an mRNA folding structure that is
incompatible with RISC access. Second, an “optimal” amount of early
protein might be required for these tumors such that too much early
protein might have growth inhibitory properties. Third, any penalty of
the RacPyV miRNA for negatively regulating viral gene expression
might be outweighed by other positive activities of the miRNA such as
targeting host tumor suppressors or even other viral proteins. We
considered the possibility that the RacPyV miRNA might be addition-
ally targeting the late transcripts, but results from luciferase reporter-
based experiments do not support this idea (Fig. S3). Deciphering
which, if any, of these models apply will require loss of function and
target identiﬁcation studies for the RacPyV miRNA in these tumors.
Given the similarities of RacPyV and MCPyV miRNAs, we
explored the possibility that MCPyV miRNA could function simi-
larly in the tumor biology of MCCs. Based on our understanding of
canonical miRNA function, our ﬁndings do not support such a
model. Meta-analysis of two different small RNA-seq studies of
MCCs and derivative cell lines, showed that the MCPyV miRNAwas
often below the limit of detection. Furthermore, in the tumors
where the MCPyV miRNA was detected, their levels never rose
above 0.025% of total miRNAs present in these cells (Table 2). In
addition, the analysis performed by Renwick et al. placed the
MCPyV miRNA in the bottom 30% of all detectable miRNAs
(Table 3). Despite the fact it has been argued that host targets of
the MCPyV miRNA could contribute to the tumor phenotype
(Lee et al., 2011), our ﬁndings strongly argue that MCPyV miRNAs
are so low in MCCs as to be insigniﬁcant, at least based on the
current understanding of canonical miRNA function. These ﬁnd-
ings suggest that the process of viral genome integration and/or
the cell type of MCCs limits promoter activity or post-transcriptional
activities required for robust MCPyV miRNA expression, lending
further support that the MCPyV and RacPyV-associated tumors arise
via separate mechanisms (Dela Cruz et al., 2013; Brostoff et al., 2014).
miRNAs are generally “ﬁne-tuning regulators” that ﬁlter “tran-
scriptional noise”, and in doing so, promote homeostasis for a variety
of physiological processes (Ebert and Sharp, 2012; Gurtan and Sharp,
2013; Mendell and Olson, 2012). An emerging model for viral miRNA
function is that diverse viruses utilize miRNAs to alter both host
and viral gene expression to promote the “homeostasis” of persistent
infection (Cox and Sullivan, 2014; Kincaid and Sullivan, 2012;
Grundhoff and Sullivan, 2011). In this scenario, viral miRNAs are
expected to suppress non-beneﬁcial host and viral gene expression
to promote infected cell viability in the face of the immune response.
Although the mechanisms of persistent infection are poorly under-
stood for PyVs, the majority of PyVs that have been studied take up
long-term infections. In combination with previous work (Zhang
et al., 2014; Seo et al., 2008; Seo et al., 2009; Chen et al., 2013;
Sullivan et al., 2005, 2009; Chen et al., 2011, 2014; Broekema and
Imperiale, 2013), our current ﬁndings are consistent with a model
whereby all PyV miRNAs regulate early gene expression, with
miRNAs from individual clades of viruses possessing unique host
targets. As it is likely that most PyV-associated disease results from
dysregulated control of persistent infection, continued deciphering of
the biological activities of diverse PyV miRNAs may be useful for
understanding the genesis of PyV-associated disease.
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Table 3
Summary of small RNA library data from MCV-positive tumors and cell lines. The mcv-miR-M1-5p deep sequencing reads and their relative rank were obtained
from a previously report study on an MCC tumor and cell lines (Renwick et al., 2013).
Sample name MCC Tumor Sample MCC Cell Line
MCC10 MKL-1a MKL-1b MKL-1c MKL-2 MS-1
Total miRNA reads 138,293 361,783 434,595 197,841 190,566 448,106
mcv-miR-M1-5p reads 35 24 3 5 4 4
% of total miRNA reads 0.0253 0.0067 0.0007 0.0025 0.0021 0.0009
mcv-miR-M1-5p rank (out of total miRNAs) 196/702 273/707 544/763 395/666 426/666 506/742
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